Takeda’s orteronel (formerly known as TAK-700) may be on its way to “dog drug heaven” after an interim analysis of the ECM-PC 5 phase 3 clinical trial showed that men with advanced prostate cancer taking the drug did not live significantly longer (HR 0.894, p=0.226) than those taking an inactive placebo.  Here’s a link to the Takeda press release.

 Orteronel (TAK 700) fails in Advanced Prostate Cancer

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $129 a month (THIS SUBSCRIPTION AUTOMATICALLY BILLS YOUR CREDIT CARD EACH MONTH UNTIL YOU CANCEL) or $327 for 3 months access (does not auto renew), $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if a communications professional our Guidance to PR Professionals contained within it.